Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Podcasts
Resources
Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Galera Therapeutics
Biotech
Galera shares rise over 100% as phase 3 flop deemed an error
Galera says an error made by a CRO was discovered, and the radiotherapy complication drug did in fact work in a phase 3 study.
Annalee Armstrong
Dec 14, 2021 3:30pm
Galera shares slide as radiotherapy complication drug fails
Oct 19, 2021 11:53am
Galera reels in $150M to test radiation side effect med in phase 3
Sep 19, 2018 11:10am
Poised for phase 3, Galera's GC4419 wards off radiation side effects
Aug 20, 2018 5:00am